Recent advances in the discovery of α1-adrenoceptor agonists

Current Topics in Medicinal Chemistry

Volumn 7, Issue 2, 2007, Pages 135-145

  Bishop, Michael J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Adrenergic receptor agonist; Adrenoceptor; Alpha 1 agonist; Epinephrine; Norepinephrine

Indexed keywords

2 (2 CHLORO 5 TRIFLUOROMETHYLPHENYLIMINO)IMIDAZOLIDINE; 2 AMINO 1 (2,5 DIMETHOXYPHENYL)ETHANOL; 2 AMINO 8 METHOXY 5 METHYLTHIOTETRALIN; 3' (2 AMINO 1 HYDROXYETHYL) 4' FLUOROMETHANESULFONANILIDE; 3,4,4A,5,10,10A HEXAHYDRO 6 METHOXY 4 METHYL 9 METHYLTHIO 2H NAPHTH[2,3 B][1,4]OXAZINE; ADRENALIN; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1D ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMIDEFRINE; ANTIHYPERTENSIVE AGENT; BUSPIRONE; CIRAZOLINE; CLONIDINE; G PROTEIN COUPLED RECEPTOR; IMIDAZOLINE; METARAMINOL; METHOXAMINE; MIDODRINE; N [5 (4,5 DIHYDRO 1H IMIDAZOL 2 YL) 5,6,7,8 TETRAHYDRO 2 HYDROXY 1 NAPHTHYL]METHANESULFONAMIDE; NAPHAZOLINE; NORADRENALIN; OXYMETAZOLINE; PHENYLEPHRINE; TETRYZOLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XYLOMETAZOLINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG UTILIZATION; GENE ACTIVATION; GENE FUNCTION; HUMAN; HYPERTENSION; MOLECULAR CLONING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; URINE INCONTINENCE; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; HUMANS; RECEPTORS, ADRENERGIC, ALPHA-1; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33846100254     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779318217     Document Type: Review

References (103)

1. Oliver, G.; Schafer, E. A. The physiological action of extract of the suprarenal capsules. J. Physiol. (Lond.), 1895, 18, 230-276.
2. Ahlquist, R. P. A study of the adrenotropic receptors. Am. J. Physiol. 1948, 153, 586-600.
3. Langer, S. Z. Presynaptic regulation of catecholamine release. Biochem. Pharmacol. 1974, 23, 1793-1800.
4. 1-Adrenoceptors Subtypes. Eur. J. Pharmacol. 1999, 375, 261-276.
5. Ruffolo, R. R. Jr.; Hieble, J. P. Adrenoceptor pharmacology: urogenital applications. Eur. Urol. 1999, 36 (Suppl. 1), 17-22.
6. 1-adrenergic receptors. Cell. Signal. 1996, 8, 323-333.
7. 1- Adrenoceptors. Eur. Urol. 1999, 36(suppl 1), 2-6.
8. Hieble, J. P. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm. Acta Helv. 2000, 74, 163-171.
9. Tatro, D. S.; Ed A-Z Drug Facts (OVID on-line edition). St. Louis, Mo: Lippincott, Williams, and Wilkins 2005.
10. Ruffolo, R. R., Jr. Medicinal chemistry of adrenoceptor agonists. Drug Des. Disc. 1993, 9(3-4), 351-367.
11. Nichols, A. J.; Ruffolo, R. R. Jr. Structure-Activity Relationships for α-Adrenoceptor Agonists and Antagonists. Prog. Basic Clin. Pharmacol. 1991, 8, 75-114.
12. Ruffolo, R. R., Jr.; Bondinell, W.; Hieble, J. P. α- and β- Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications. J. Med. Chem. 1995, 38(19),3691-3716.
13. 1-adrenoceptor agonists based on hexahydronaphth[2,3-b]- 1,4-oxazines and octahydrobenzo[g]quinolines. J. Med. Chem. 1992, 35(3), 480-489.
14. Ruffolo, R. R., Jr.; Turowski, B. S.; Patil, P. N. Lack of cross-desensitization between structurally dissimilar α-adrenoceptor agonists. J. Pharm. Pharmacol. 1997, 29, 378-380.
15. 1-adrenoceptor subtypes A, B, D and L. Eur. J. Pharmacol. 1999, 378(1), 69-83.
16. Yamamoto, Y.; Koike, K. Characterization of α-adrenoceptor-mediated contraction in the mouse thoracic aorta. Eur. J. Pharmacol. 2001, 424(2), 131-140.
17. 1-adrenoceptors: consensus update. Pharmacol. Rev. 1995, 47(2), 267-70
18. 1-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci. 1986, 7, 347-349.
19. Ford, A. P. D. W.; Daniels, D. V.; Chang, D. J.; Gever, J. R.; Jasper, J. R.; Lesnick, J. D.; Clarke, D. E. Pharmacological pleiotropism of the human recombinant alpha 1A-adrenoreptor: implications for alpha 1-adrenoceptor classification. Br. J. Pharmacol. 1997, 121, 1127-1135.
20. 1-Adrenergic signaling mechanisms in contraction of resistance arteries. Rev. Phys. Bioc. Pharmacol. 2003, 150, 91-139.
21. Hieble, J. P.; Ruffolo, R. R., Jr. Adrenergic receptors. In: Understanding G Protein-Coupled Receptors and Their Role in the CNS; Pangalos, M. N.; Davies, C. H.; Eds.; Oxford, U.K.: Oxford University Press, 2002: 205-220.
22. 1- Adrenergic receptor regulation: basic science and clinical implications. Pharmacol. Ther. 2000, 88(3), 281-309.
23. Hieble, J. P.; Ruffolo, R. R., Jr. α-Adrenoceptor Agonists and Antagonists. Drugs Pharm. Sci. 1998, 89, 231-252.
24. 1-adrenoceptor subtypes in mouse carotid arteries using knockout mice. Brit. J. Pharmacol. 2005, 144(4), 558-565.
25. 1- Adrenergic receptor subtypes: non-identical triplets with different dancing partners? Life Sci. 2003, 74(4), 411-418.
26. 1-adrenoceptors. Bioc. Soc. Trans. 2004, 32(5), 847-850.
27. Uberti, M. A.; Hall, R.A.; Minneman, K. P. Subtype-specific dimerization of alpha-1-adrenoceptors: Effects on receptor expression and physiological properties. Mol. Pharmacol. 2003, 64(6), 1379-1390.
28. 1-Adrenergic Receptor Subtypes. Mol. Pharmacol. 1994, 46, 929-936.
29. Craig, D. A.; Forray, C. C.; Gluchowski, C.; Branchek, T. A. PCT Int. Appl. WO 9638143 A1 (1996) Chem. Abstr. 126:117873.
30. Haab, F.; Zimmern, P E.; Leach, G. E. Female stress urinary incontinence due to intrinsic sphincteric deficiency: recognition and management. J. Urol. 1996, 156, 3-17.
31. Jonas, D. Treatment of female stress incontinence with midodrine: preliminary report. J. Urol. 1977, 118, 980-982.
32. Obrink, A.; Bunne, G. The effect of alpha-adrenergic stimulation in stress incontinence. Scand. J. Urol. Nephrol. 1978, 12(3), 205-208.
33. Wein, A. J. Urinary incontinence: classification and therapeutic guidelines. Seminars in Urology. 1989, 7(2), 59-64.
34. Alberts, P.; Bergstrom, P.A.C.; Fredrickson, M.G. Characterization of the functional α-adrenoceptor subtype in the isolated female pig urethra. Eur. J. Pharmacol. 1999, 371, 31-38.
35. Taniguchi, N.; Ukai, Y.; Tanaka, T.; Yano, J.; Kimura, K.; Moriyama, N.; Kawabe, K. Identification of alpha1-adrenoceptor subtypes in the human prostatic urethra. Naunyn-Schmiedeberg's Arch. Pharmacol. 1997, 355, 412-416.
36. 1-adrenoceptor agonists in isolated human male and female urethra. BJU Int. 1999, 84, 515-520.
37. 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Eur. J. Pharmacol. 1996, 318, 117-122.
38. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 351(1), 2-9.
39. 1- adrenoceptors. Eur. J. Pharmacol. 1995, 291, 327-334.
40. Pouzet, P. A.; Esser, F.; Kitagawa, H.; Ishiguro, N.; Muramatsu, I. PCT Int. Appl. WO 02060421 A2 (2002), Chem. Abst. 137:145596.
41. Esser, F.; Staehle, H.; Luettke, S.; Muramatsu, I.; Kitagawa, H.; Uchida, S. DE 19514579-A (1996), Chem. Abstr. 126:8114.
42. Esser, F.; Kitagawa, H.; Muramatsu, I.; Ishiguro, N.; Pouzet, P. Eur. Pat. Appl. EP 1333028 A1 (2003) Chem. Abst. 139:149634.
43. Esser, F.; Pouzet, P.; Kitagawa, H.; Sakai, K.; Muramatsu, I. PCT Int. Appl. WO 2002032876 A2 (2002), Chem. Abst. 136:325543.
44. Esser, F.; Pouzet, P.; Kitagawa, H.; Sakai, K.; Muramatsu, I.; Hoffmann, M. DE 10106214 A1 (2002), Chem. Abst. 137:169519.
45. 1A Receptor Subtype. J. Pharmacol. Exp. Ther. 1995, 274, 97-103.
46. 1A Receptor Agonist. J. Med. Chem. 1996, 39, 4116-4119.
47. Altenbach, R. J.; Meyer, M. D.; Kerwin, J. F.; Holladay, M. W.; Khilevich, A.; Kolasa, T.; Rohde, J. J.; Carroll, W. A., WO 0007997 A1 (2000), Chem. Abstr. 132:166236
48. 1A-adrenergic agonist, in in vitro and in vivo models of urethral function. Life. Sci. 2001, 70, 181-197.
49. 1A-adrenoceptor agonist. J. Med. Chem. 2004, 47, 3220-3235.
50. Carroll, W. A.; Altenbach, R. J.; Buckner, S. A.; Brioni, J. D.; Brune, M. E.; Kolasa, T.; Meyer,M. D.; Sullivan, J. P. In vitro and in vivo characterization of alpha-1A selective agonists and their utility for stress incontinence. Med. Chem. Res. 2004, 13(3/4), 134-148.
51. 1-Adrenoceptor Ligand with an Enhanced in Vitro and in Vivo Profile Relative to Phenylpropanolamine and Midodrine. J. Med. Chem. 2002, 45, 4395-4397.
52. 1B/D Antagonist Properties. J. Urol. 2001, 165(5), 140.
53. Seif, L. S.; Hannick, S. M.; Plata, D. J.; Morton, H. E.; Sharma, P. N. A novel large scale hydrogenation strategy of N, N-dimethyl 4- (acetoxy-3-nitrophenylmedthyl)-1-H-imidazole -1-sulfonamide, a key intermediate in the synthesis of ABT-866. Chem. Ind. 2003, 89(Catalysis of Organic Reactions), 633-641.
54. Yamashita, H.; Fujiwara, J.; Mori. H.; Kawai, K.; Oyabe, A. JP 11049771 A2 (1997) Chem Abstr. 130:232522.
55. Komatsu, K.; Watanabe, T.; Sasho, S.; Okumura, H.; Ide, S.; Shirakura, S. JP 03252863 A2 (2003), Chem.Abst. 139:230779.
56. Bigham, E. C.; Bishop, M. J.; Drewry, D. H.; Garrison, D. T.; Hodson, S. J.; Navas, F.; Speake, J. D. PCT Int. Appl. WO 0066563 A1 (2000), Chem. Abstr. 133:350215.
57. 1a Subtype Selective 2'-Carboxylic Acid Esters and Amides. Bioorg. Med. Chem. Lett. 2001, 11, 2871-2874.
58. 1a subtype selective 2′-heteroaryl compounds. Bioorg. Med. Chem. Lett. 2003, 13(6), 1183-1186.
59. 1-Adrenoceptor activation: A comparison of 4-(Anilinomethyl)imidazoles and 4-(Phenoxymethyl)imidazoles to related 2-imidazolines. Bioorg. Med. Chem. Lett. 2002, 12(23), 3449-3452.
60. 1A Subtype Selective 2′-Alkylsulfonyl-Substituted. Analogues. J. Med. Chem. 2002, 45(11), 2229-2239.
61. 1A Adrenergic Receptor Agonists: 2′-Heteroaryl and 2′-Oxime Ether Series. Bioorg. Med. Chem. Lett. 2002, 12(4), 575-579.
62. 1A Subtype Selective 2′- Heteroaryl-2-(phenoxymethyl)imidazolines. Bioorg. Med. Chem. Lett. 2002, 12(3), 471-475.
63. 1a-selective anilinomethylimidazolines for the treatment of stress urinary incontinence. 221th, ACS National Meeting, San Diego, CA. 2001, MEDI 221.
64. Greenhouse, R.; Jaime-Figueroa, S.; Raptova, L. PCT Int. Appl. WO 03064387 A2 (2003), Chem. Abstr. 139:149525.
65. Dillon, M. P; Lin, C. J. ; Moore, A. G.; O'Yang, C.; Zhai, Y. PCT Int. Appl. WO 040224973 A1 (2004), Chem. Abstr. 141:410926.
66. Cournoyer, R. L.; Keitz, P. F.; O'Yang, C.; Yasuda, D. M. Eur. Pat. Appl. EP 887346 A2 (1998), Chem Abst. 130:95391.
67. Dillon, M. P; Lin, C. J.; O'Yang, C.; Zhang, X. PCT Int. Appl. WO 03091236 A1 (2003), Chem. Abstr. 139:364930.
68. 1A/ 1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. B.J U. Internat. 2004, 93, 162-170.
69. 1A/ 1L-adrenoceptor partial agonist in women with stress urinary incontinence. B.J U. Internat. 2004, 93, 73-83.
70. Philippo, C.; Mougenot, P.; Bovy, P. PCT Int. Appl. WO842679 A1 (1998), Chem. Abst. 129:275916
71. Bovy, P. R.; Braun, A.; Philippo, C. PCT Int. Appl. (2001), Chem. Abst. 135:19561.
72. Bovy, P. R.; Mougenot, P.; Philippo, C. PCT Int. Appl. WO00061554 A1 (2000), Chem. Abst. 133:309841.
73. Bovy, P. R.; Mougenot, P.; Philippo, C. PCT Int. Appl. WO00061553 A1 (2000), Chem. Abst. 133: 309840.
74. Philippo, C.; Marcimak, G.; Bovy, P. R. FR 2781800 A1 (2000), Chem. Abst. 133:237852.
75. Philippo, C.; Marciniak, G.; Bovy, P. R. FR 2781799 A1 (2000), Chem.Abst. 133:237851
76. Philippo, C.; Braun, A.; Bovy, P. R. PCT Int. Appl. WO0006219 A1 (2000), Chem. Abst. 133:164008
77. Philippo, C.; Mougenot, P.; Defosse, G.; Braun, A.; Bovy, P. R. PCT Int. Appl. WO00029379 A1 (2000), Chem Abst 133:460.
78. Philippo, C.; Defosse, G.; Mougenot, P.; Braun, A.; Bovy, P. R. PCT Int. Appl. WO00015617 A1 (2000), Chem. Abst. 132:236998.
79. Philippo, C.; Auboussier, S.; Crespin, O.; Bovy, P.; Courtemanche, G. PCT Int. Appl. WO9833793 A1 (1998), Chem Abst. 129:175559.
80. Philippo, C.; Crespin, O.; Bovy, P. FR2752840 A1 (1998), Chem. Abst. 128:243944.
81. Philippo, C.; Orts, M.-C.; Crespin, O.; Bovy, P. PCT Int. Appl. WO9808834 A1 (1998), Chem. Abst. 128:217277.
82. Philippo, C.; Courtemanche, G.; Fett, E.; Orts, M. C.; Bovy, P.; O'Connor, S. E.; Galzin, A. M. PCT Int. Appl. WO9732870 A1 (1997), Chem. Abst. 127:278131.
83. Bovy, P. R.; Braun, A.; Philippo, C. PCT Int. Appl. WO01044197 A2 (2001), Chem. Abst. 135:46114.
84. Jeon,. Y. T.; Li, C.; Forray, C.; Jorgensen, V.; Nagorny, R.; Branchek, T. A.; Gluchowski, C. Synthesis of Analogs of SDZ NVI 085: Pharmacological Evaluation at Cloned Human α Adrenergic Receptors. 213th ACS National Meeting, San Francisco, CA. 1997, MEDI 22.
85. Tanimitsu, N.; Yajin, K.; Sasa, M.; Tsuru, H. Alpha(1)-adrenoceptor subtypes and effect of alpha(1L)-adrenoceptor agonist NS-49 on guinea pig nasal mucosa vasculature. Eur. J. Pharmacol. 2000, 387(1), 73-78.
86. 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc., Natl. Acad. Sci. U.S.A. 2002, 99, 9474-9479.
87. 1-adrenoceptor. Eur. J. Pharmacol. 1995, 272, R5-R6.
88. 1D-adrenoceptor: molecular and cellular characteristics and integrative roles. Eur. J. Pharmacol. 2004, 500, 113-120.
89. Wess, J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J. 1997, 5, 346-354.
90. Robinson, P. K.; Cohen, G. B.; Zhukovsky, E. A.; Oprian, D. D. Constitutively active mutants of rhodopsin. Neuron, 1992, 9, 719-725.
91. 1b-adrenergic receptor is initiated by disruption of an intrahelical salt bridge constraint. J. Biol. Chem. 1996, 271, 26318-28323.
92. Cavalli, A.; Fanelli, F.; Taddei, C.; De Benedetti, P. G.; Cotecchia, S. Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes. FEBS Lett. 1996, 399, 9-13.
93. 1-Adrenergic Receptors. Adv. Pharmacol. 1998, 42, 398-403.
94. 1-Adrenergic Receptor Agonist Binding and Activation. J. Biol. Chem. 1996, 271(11), 6322-6327.
95. Hieble, J. P.; Hehr, A.; Li, Y-O.; Ruffolo, R-R., Jr. Molecular basis for the stereoselective interactions of catecholamines with (α-adrenoceptors. Proc. West. Pharmacol. Soc. 1998, 41, 225-228.
96. 1-adrenergic receptor is a key switch residue involved in activation and chatechol ring aromatic bonding. J. Biol. Chem. 1999, 274, 16320-1630.
97. 1-adrenergic receptors. J. Biol. Chem. 2000, 275, 11698-11705.
98. 1b-Adrenergic Receptor Highlight the Role of the Helix 3/Helix 6 Interface in Receptor Activation. Mol Pharmacol 2002, 61, 1025-1032.
99. 1b-adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action. Pharm. Acts Helv. 2000, 74, 173-179.
100. Perez, D M.; Hwa, J.; Gaivin, R.; Mathur, M.; Brown, F.; Graham, R. M. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol. Pharmacol. 1996, 49, 112-122.
101. 1-adrenergic receptor antagonist binding. J. Biol. Chem. 2001, 276, 25366-25371.
102. 1-Adrenergic Receptor Subtype Selective Agonist Binding. J. Biol. Chem. 1995, 270(39), 23189-23195.
103. 1A-Adrenergic Receptor. Recep. Chan. 2004, 10, 109-116.